Media coverage about Emergent Biosolutions (NYSE:EBS) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Emergent Biosolutions earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.4128982969215 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

EBS has been the subject of a number of research analyst reports. Zacks Investment Research lowered Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 19th. Chardan Capital lifted their target price on Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Goldman Sachs Group initiated coverage on Emergent Biosolutions in a report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Shares of Emergent Biosolutions (EBS) traded down $0.58 on Friday, hitting $44.44. The company had a trading volume of 733,653 shares, compared to its average volume of 305,953. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a one year low of $27.94 and a one year high of $51.25. The company has a market capitalization of $2,195.56, a price-to-earnings ratio of 26.30, a P/E/G ratio of 0.92 and a beta of 1.28.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 40,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $40.37, for a total transaction of $1,614,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerome M. Hauer sold 5,152 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $50.91, for a total value of $262,288.32. Following the sale, the director now directly owns 23,797 shares of the company’s stock, valued at approximately $1,211,505.27. The disclosure for this sale can be found here. Insiders sold 165,722 shares of company stock valued at $7,219,341 in the last ninety days. 16.50% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Emergent Biosolutions (EBS) Share Price” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with's FREE daily email newsletter.